1887
Rapid communication Open Access
Like 0

Abstract

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9).

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.28.2100634
2021-07-15
2021-07-27
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.28.2100634
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/28/eurosurv-26-28-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.28.2100634&mimeType=html&fmt=ahah

References

  1. Swedish Public Health Agency. Recommendation for a 65-year age limit for AstraZeneca's vaccine remains. [Swedish]. Stockholm: Folkhälsomyndigheten; 2021. Available from: https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/april/rekommendation-om-aldersgrans-pa-65-ar-for-astrazenecas-vaccin-kvarstar/
  2. Haute Autorité de Santé. Covid-19: what vaccine strategy for people under 55 who have already received a dose of AstraZeneca? [French]. Saint-Denis: Haute Autorité de Santé; 2021. Available from: https://www.has-sante.fr/jcms/p_3260335/
  3. Danish Health Authority. Denmark continues its vaccine rollout without the COVID-19 vaccine from AstraZeneca. Copenhagen: Danish Health Authority; 2021. Available from: https://www.sst.dk/en/English/news/2021/Denmark-continues-its-vaccine-rollout-without-the-COVID-19-vaccine-from-AstraZeneca
  4. Public Health Agency of Canada. NACI rapid response: Interchangeability of authorized COVID-19 vaccines. Ottawa: Public Health Agency of Canada; 2021. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/rapid-response-interchangeability.html
  5. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043-6.  https://doi.org/10.1016/S0140-6736(21)01115-6  PMID: 33991480 
  6. NHS England. COVID-19 Vaccinations. London: NHS England; 2021. Available from: https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-vaccinations/
  7. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2020
  8. Our World in Data. Coronavirus (COVID-19) Vaccinations. Oxford: Our World in Data; 2021. Available from: https://ourworldindata.org/covid-vaccinations
  9. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. London: Public Health England; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf
  10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  11. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.  https://doi.org/10.1016/S0140-6736(20)31604-4  PMID: 32702298 
  12. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens. medRxiv. 2021: 2021.06.13.21258859.
  13. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv. 2021: 2021.05.30.21257971.
  14. Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv. 2021: 2021.05.19.21257334.
  15. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121-30.  https://doi.org/10.1016/S0140-6736(21)01420-3  PMID: 34181880 
  16. Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021;12(1):2893.  https://doi.org/10.1038/s41467-021-23173-1  PMID: 34001897 
/content/10.2807/1560-7917.ES.2021.26.28.2100634
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error